A Patient-Derived 3D Bioprinted Colorectal Cancer-Stroma-Immune Triad Model Uncovers Microenvironmental Mechanisms of Chemoresistance and Immune Evasion
Construction of a 3D Multicellular Bioprinted Human Colorectal Cancer Immune-Stromal Microenvironment Model and Its Clinical Translational Research
Colorectal cancer (CRC) has shifted toward a patient-personalized precision medicine paradigm; however, the high heterogeneity and complex tumor microenvironment (TME) of CRC restrict the development of individualized therapy, and existing preclinical models and multi-omics technologies are insufficient to broadly benefit patients. Building on previous research, this project intends to use 3D multicellular bioprinting (3DMP) to incorporate key TME components-cancer-associated fibroblasts (CAFs) and PBMC immune cells-to construct patient-derived CRC-CAFs/PBMC 3DMP models, aiming to apply them to personalized clinical drug screening and prognosis prediction, and to combine them with multi-omics technologies to advance preclinical research on CRC. The implementation of this study will help address the bottleneck of the lack of broadly applicable preclinical models for advancing CRC precision therapy. It has major clinical translational value, will bring significant changes to CRC preclinical research platforms, and will help promote the development of cancer precision medicine.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名：Yilei Mao, MD PHD
- 电话号码：8600-010-69156042
- 邮箱：pumch-liver@hotmail.com
学习地点
-
-
Zhejiang
-
Ningbo、Zhejiang、中国
- 招聘中
- Ningbo Medical Center Lihuili Hospital
-
接触：
- Zhou Bo
- 电话号码：8600-0574-87018701
- 邮箱：1955729746@qq.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Clinically and pathologically proven colorectal cancer patients are considered as potential candidates of this study. Medical history will be thouroughly taken by clincal practicitioners. Only patients older than 18 years will be included. Those with medical hostory of other malignancies or serious diseases will be excluded. Patients who are not able to sign the informed consent independently will not be included in this study. All the patients included in this study will receive adjuvant/neoadjuvant chemotherapy and surgical resection for the treatment of CRC.
描述
Inclusion Criteria:
- More than 18 years old
- Diagnosed as colorectal cancer with or without liver metastases before
- Pathologically proven colorectal cancer after surgery
Exclusion Criteria:
- Medical history with other malignancies or serious diseases
- Disable to sign the informed consent independently
学习计划
研究是如何设计的？
设计细节
- 观测模型：COHORT
- 时间观点：PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Patients with colorectal cancer who underwent surgical resection received adjuvant chemotherapy
Surgical resection will be performed for locoregional lesions. Regimens of adjuvant chemotherapy are directed by clinical guidance and experience. |
Surgical resection will be performed for locoregional lesions. Regimens of adjuvant chemotherapy are directed by clinical guidance and experience. |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Response of 3D tumor models/organoids to the same chemotherapy drugs as the corresponding patients.
大体时间：2025.05-2026.12
|
The investigators will establish and culture 3D colorectal cancer models and organoids. The 3D models and organoids will be treated with the same chemotherapy drugs as the corresponding patients. The viability of the 3D tumor models and organoids will be observed after treatment and the IC50 of each drug will be calculated. The correlation of 3D model/organoid sensitivity and the patient response will be analyzed. |
2025.05-2026.12
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Response of the colorectal cancer patients to adjuvant chemotherapy.
大体时间：2025.05-2026.12
|
The response to adjuvant chemotherapy will be evaluated according to PFS. Regular follow-ups will be conducted, and PFS is difined as the interval between the date of surgery and the date of last follow-up or recurrence/progression. |
2025.05-2026.12
|
合作者和调查者
调查人员
- 首席研究员：Yilei Mao, MD PHD、Peking Union Medical College Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CRC-CAFs-3DP-Bioprint
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
Individual participant data (IPD) can be accessed with reasonable requests via e-mail. IPD will be shared after the study is completed.
IPD 共享时间框架
The IPD data will available after the study is completed.
IPD 共享访问标准
Data can be accessed via e-mail with reasonable requests.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.